Hong Kong

China's Largest AI-Themed ETF Hits Milestone, Reflecting Promising Global Trend and Growing Investor Interest

Retrieved on: 
Monday, December 18, 2023
ETF, Intelligence, E Fund Management, OpenAI, Qualcomm, AI, AUM, Environment, Qualcomm Snapdragon, Antirrhinum, Hong Kong

HONG KONG, Dec. 18, 2023 /PRNewswire/ -- As of December 13th, the E Fund CSI Artificial Intelligence Thematic ETF, the largest of its category, reached a milestone with AUM approaching US$617 million.

Key Points: 
  • HONG KONG, Dec. 18, 2023 /PRNewswire/ -- As of December 13th, the E Fund CSI Artificial Intelligence Thematic ETF, the largest of its category, reached a milestone with AUM approaching US$617 million.
  • The recent AI hype has sparked a sense of excitement among investors and the E Fund CSI Artificial Intelligence Thematic ETF recorded a remarkable weekly inflow of US$14 million in December.
  • Globally, the growing momentum of AI was mainly driven by rapid advancement in large language models and expanded hardware opportunities.
  • In China, the trajectory of AI development, particularly regarding self-developed large language models and computing power, is ramping up.

China's Largest AI-Themed ETF Hits Milestone, Reflecting Promising Global Trend and Growing Investor Interest

Retrieved on: 
Monday, December 18, 2023
ETF, Intelligence, E Fund Management, OpenAI, Qualcomm, AI, AUM, Environment, Qualcomm Snapdragon, Antirrhinum, Hong Kong

HONG KONG, Dec. 18, 2023 /PRNewswire/ -- As of December 13th, the E Fund CSI Artificial Intelligence Thematic ETF, the largest of its category, reached a milestone with AUM approaching US$617 million.

Key Points: 
  • HONG KONG, Dec. 18, 2023 /PRNewswire/ -- As of December 13th, the E Fund CSI Artificial Intelligence Thematic ETF, the largest of its category, reached a milestone with AUM approaching US$617 million.
  • The recent AI hype has sparked a sense of excitement among investors and the E Fund CSI Artificial Intelligence Thematic ETF recorded a remarkable weekly inflow of US$14 million in December.
  • Globally, the growing momentum of AI was mainly driven by rapid advancement in large language models and expanded hardware opportunities.
  • In China, the trajectory of AI development, particularly regarding self-developed large language models and computing power, is ramping up.

Bakkt Announces Expansion of International Footprint and Custody Client Base

Retrieved on: 
Thursday, November 9, 2023
Technology, Payments, Finance, Fintech, Professional Services, Digital Cash Management, Digital Assets, Blockchain, Data Management, Cryptocurrency, Other Professional Services, NYSE, Hong Kong, Bakkt

Bakkt Holdings, Inc. (NYSE: BKKT) announced today its planned expansion of crypto capabilities into numerous international markets with both existing and newly-signed clients by year end.

Key Points: 
  • Bakkt Holdings, Inc. (NYSE: BKKT) announced today its planned expansion of crypto capabilities into numerous international markets with both existing and newly-signed clients by year end.
  • Europe: Bakkt and Hapi also expect to launch in Spain by the end of 2023.
  • In addition, Bakkt will provide crypto trading and custody services in the UK and EU to crypto app 3.0verse, planning to launch by year end.
  • In addition to international expansion, Bakkt continues to expand with institutionally-backed clients domestically.

GenScript ProBio Signs Viral Vector Manufacturing MOU With Curocell for Next-Generation CAR-T Therapy

Retrieved on: 
Friday, November 10, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Cardiology, Biotechnology, Stem Cells, Health, Other Science, Antigen, GMP, Gene, CDMO, IND, GenScript Biotech, Virus, Cancer, Partnership, Growth, Immunotherapy, CGT, MOU, Vaccine, Hong Kong

On November 10, a global multimodality CDMO, GenScript ProBio and specialized CAR-T therapy firm Curocell signed a strategic partnership MOU for the production of viral vectors necessary for the development of next generation of CAR-T therapy, marking another significant step in their ongoing collaboration.

Key Points: 
  • On November 10, a global multimodality CDMO, GenScript ProBio and specialized CAR-T therapy firm Curocell signed a strategic partnership MOU for the production of viral vectors necessary for the development of next generation of CAR-T therapy, marking another significant step in their ongoing collaboration.
  • Viral vectors are vehicles for drug delivery that utilize viruses to transport genetic material to the cellular interior.
  • The demand for viral vectors is rapidly increasing due to the recent growth of the gene therapy market, which uses CAR-T therapy as its main active ingredient.
  • However, it has been noted that a shortage of GMP facilities producing viral vectors is causing delays in the development of gene therapies, including CAR-T therapy.

RISKTHINKING.AI AWARDED 2ND PLACE IN HKMA'S GREEN FINTECH COMPETITION

Retrieved on: 
Thursday, December 14, 2023
Carbon, Disclosure, Sustainability, Climate change, VELO, Climate, Humble, Texas, Conference, Hong Kong Monetary Authority, Climate risk, Climate risk management, HKMA, Sustainable finance, Bloomberg L.P., Medical device, Cryptocurrency, Renewable energy, Hong Kong

TORONTO, Dec. 14, 2023 /CNW/ - Riskthinking.AI, a Toronto-based climate risk data and analytics provider, proudly announces its achievement of securing second place in the Hong Kong Monetary Authority (HKMA) Green Fintech Competition, held as part of the Green and Sustainable Banking Conference.

Key Points: 
  • TORONTO, Dec. 14, 2023 /CNW/ - Riskthinking.AI, a Toronto-based climate risk data and analytics provider, proudly announces its achievement of securing second place in the Hong Kong Monetary Authority (HKMA) Green Fintech Competition, held as part of the Green and Sustainable Banking Conference.
  • The HKMA Green Fintech Competition was a central focus of the conference.
  • The competition sought market-ready solutions in four categories: Net-zero Transition, Climate Risk Management, Green and Sustainable Finance, and Sustainability or Climate-related Disclosure and Reporting.
  • HKMA's recognition of Riskthinking.AI in the Green Fintech Competition underscores its achievement in innovating accessible, comprehensive, and dependable solutions for measuring climate-related financial risk worldwide, including in Asia.

RISKTHINKING.AI AWARDED 2ND PLACE IN HKMA'S GREEN FINTECH COMPETITION

Retrieved on: 
Thursday, December 14, 2023
Carbon, Disclosure, Sustainability, Climate change, VELO, Climate, Humble, Texas, Conference, Hong Kong Monetary Authority, Climate risk, Climate risk management, HKMA, Sustainable finance, Bloomberg L.P., Medical device, Cryptocurrency, Renewable energy, Hong Kong

TORONTO, Dec. 14, 2023 /PRNewswire/ - Riskthinking.AI, a Toronto-based climate risk data and analytics provider, proudly announces its achievement of securing second place in the Hong Kong Monetary Authority (HKMA) Green Fintech Competition, held as part of the Green and Sustainable Banking Conference.

Key Points: 
  • TORONTO, Dec. 14, 2023 /PRNewswire/ - Riskthinking.AI, a Toronto-based climate risk data and analytics provider, proudly announces its achievement of securing second place in the Hong Kong Monetary Authority (HKMA) Green Fintech Competition, held as part of the Green and Sustainable Banking Conference.
  • The HKMA Green Fintech Competition was a central focus of the conference.
  • The competition sought market-ready solutions in four categories: Net-zero Transition, Climate Risk Management, Green and Sustainable Finance, and Sustainability or Climate-related Disclosure and Reporting.
  • HKMA's recognition of Riskthinking.AI in the Green Fintech Competition underscores its achievement in innovating accessible, comprehensive, and dependable solutions for measuring climate-related financial risk worldwide, including in Asia.

CICG: Visiting the "Sea of Flowers" in Zhongshan

Retrieved on: 
Thursday, December 14, 2023
Painting, Eye, Central Plain, Tourism, Sea, Flower, Chrysanthemum, Translation, Interpretation, Meat, Vitality, Friends, Tongue, Exhibition, Southern Song dynasty coinage, Leisure, Economic development, Furniture, Xiaolan, Hong Kong

It is said that the small chrysanthemum has witnessed the development and change of this land over thousands of years.

Key Points: 
  • It is said that the small chrysanthemum has witnessed the development and change of this land over thousands of years.
  • In 1736, Xiaolan people held a "chrysanthemum test" to test each family's chrysanthemum art, which has become the earliest prototype of the chrysanthemum fair.
  • In 2006, the "Xiaolan Chrysanthemum Fair" was included in the first batch of "National Intangible Cultural Heritage" protection lists.
  • "In Japan, chrysanthemum culture also has a long history, and Xiaolan Chrysanthemum Fair has really opened my eyes.

CICG: Visiting the "Sea of Flowers" in Zhongshan

Retrieved on: 
Thursday, December 14, 2023
Painting, Eye, Central Plain, Tourism, Sea, Flower, Chrysanthemum, Translation, Interpretation, Meat, Vitality, Friends, Tongue, Exhibition, Southern Song dynasty coinage, Leisure, Economic development, Furniture, Xiaolan, Hong Kong

It is said that the small chrysanthemum has witnessed the development and change of this land over thousands of years.

Key Points: 
  • It is said that the small chrysanthemum has witnessed the development and change of this land over thousands of years.
  • In 1736, Xiaolan people held a "chrysanthemum test" to test each family's chrysanthemum art, which has become the earliest prototype of the chrysanthemum fair.
  • In 2006, the "Xiaolan Chrysanthemum Fair" was included in the first batch of "National Intangible Cultural Heritage" protection lists.
  • "In Japan, chrysanthemum culture also has a long history, and Xiaolan Chrysanthemum Fair has really opened my eyes.

CLPS Incorporation Expands Overseas Credit Card Business with the Acquisition of Purple Potato Finance

Retrieved on: 
Thursday, December 14, 2023
Workforce, Acquisition, CLPS, Potato, QCC, Hong Kong

HONG KONG, Dec. 14, 2023 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS), today announced that its wholly-owned subsidiary, Qinson Credit Card Services Limited ("QCC"), has successfully acquired 100% equity of Purple Potato Finance Limited ("Purple Potato").

Key Points: 
  • HONG KONG, Dec. 14, 2023 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS), today announced that its wholly-owned subsidiary, Qinson Credit Card Services Limited ("QCC"), has successfully acquired 100% equity of Purple Potato Finance Limited ("Purple Potato").
  • This strategic move enables CLPS to broaden its credit card business within the Hong Kong market.
  • Its expertise extends across various countries, currencies, and credit card system modules, delivering successful implementation of credit card projects for numerous large banks and financial institutions.
  • This move not only expands our business scope, but also seamlessly integrates our credit card services, offering a comprehensive solution for end-users.

Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)

Retrieved on: 
Thursday, December 14, 2023
Pancreatic cancer, QD, Policy, Therapy, Contributor License Agreement, NMPA, EMA, Patient, TGCT, BTD, U.S. FDA, FDA, FTD, License, Tenosynovial giant cell tumor, ORR, Fast Track, Merck Group, Pharmaceutical industry, Hong Kong

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients that are not amenable to surgery.

Key Points: 
  • SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients that are not amenable to surgery.
  • Previously, pimicotinib was granted the breakthrough therapy designation ("BTD") by the U.S. FDA for TGCT in January, 2023.
  • Fast Track is a policy designed to facilitate the development and expedite the review of drugs in order to treat serious conditions and fulfill unmet medical needs.
  • Pimicotinib is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor, independently developed by Abbisko Therapeutics.